PT2947072T - 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas - Google Patents

1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas

Info

Publication number: PT2947072T
Authority: PT; Portugal
Prior art keywords: dimethoxyquinazolin; methylpropan; isoxazol; yloxy; trifluoro
Prior art date: 2008-03-17

Application number

PT151661410T

Other languages

English (en)

Inventor

G Sprankle Kelly

Abraham Sunny

S Bhagwat Shripad

t campbell Brian

Chao Qi

Faraoni Raffaella

W Holladay Mark

G Lai Andiliy

W Rowbottom Martin

Setti Eduardo

Original Assignee

Ambit Biosciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-17

Filing date

2009-03-17

Publication date

2016-12-06

2009-03-17 Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp

2016-12-06 Publication of PT2947072T publication Critical patent/PT2947072T/pt

Links

DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
102000009929 raf Kinases Human genes 0.000 title 1
108010077182 raf Kinases Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Transplantation (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT151661410T 2008-03-17 2009-03-17 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas PT2947072T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6976308P	2008-03-17	2008-03-17
US11050808P	2008-10-31	2008-10-31

Publications (1)

Publication Number	Publication Date
PT2947072T true PT2947072T (pt)	2016-12-06

Family

ID=40852165

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT151661410T PT2947072T (pt)	2008-03-17	2009-03-17	1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
PT97224182T PT2268623E (pt)	2008-03-17	2009-03-17	Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT97224182T PT2268623E (pt)	2008-03-17	2009-03-17	Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos

Country Status (22)

Country	Link
US (5)	US8618289B2 (pt)
EP (3)	EP3147281A1 (pt)
JP (1)	JP5542793B2 (pt)
KR (2)	KR101713501B1 (pt)
CN (2)	CN106146484A (pt)
AU (1)	AU2009226136B2 (pt)
BR (1)	BRPI0906186A2 (pt)
CA (2)	CA2718123C (pt)
DK (2)	DK2268623T3 (pt)
EA (1)	EA019350B1 (pt)
ES (2)	ES2547406T3 (pt)
HU (2)	HUE025197T2 (pt)
IL (1)	IL207793A (pt)
MX (1)	MX2010010172A (pt)
MY (1)	MY161576A (pt)
NZ (1)	NZ587907A (pt)
PL (2)	PL2268623T3 (pt)
PT (2)	PT2947072T (pt)
SG (2)	SG191678A1 (pt)
SI (2)	SI2268623T1 (pt)
WO (1)	WO2009117080A1 (pt)
ZA (1)	ZA201006524B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011513332A (ja) *	2008-02-29	2011-04-28	アレイバイオファーマ、インコーポレイテッド	癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
KR20100122505A (ko) *	2008-02-29	2010-11-22	어레이 바이오파마 인크.	Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
JP2011513331A (ja) *	2008-02-29	2011-04-28	アレイバイオファーマ、インコーポレイテッド	ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
CA2716947A1 (en) *	2008-02-29	2009-09-11	Array Biopharma Inc.	Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP3147281A1 (en)	2008-03-17	2017-03-29	Ambit Biosciences Corporation	Quinazoline derivatives as raf kinase modulators and methods of use thereof
EP2398797B1 (en) *	2009-02-17	2013-11-06	Boehringer Ingelheim International GmbH	Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
WO2011056939A1 (en) *	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
US9024041B2 (en)	2010-04-08	2015-05-05	Respivert Ltd.	P38 MAP kinase inhibitors
WO2011158044A2 (en)	2010-06-17	2011-12-22	Respivert Limited	Respiratory formulations and compounds for use therein
CA2835835C (en)	2011-05-13	2019-04-02	Array Biopharma Inc.	Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
ES2725790T3 (es)	2011-08-26	2019-09-27	Neupharma Inc	Algunas entidades químicas, composiciones, y métodos
CN115403531A (zh)	2011-09-14	2022-11-29	润新生物公司	作为激酶抑制剂的化学实体、组合物及方法
KR101995274B1 (ko)	2011-10-03	2019-07-02	레스피버트 리미티드	P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
SG11201402004YA (en)	2011-11-14	2014-05-29	Cephalon Inc	Uracil derivatives as axl and c-met kinase inhibitors
EP2806874B1 (en)	2012-01-25	2017-11-15	Neupharma, Inc.	Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
EP2626073A1 (en) *	2012-02-13	2013-08-14	Harmonic Pharma	Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
US20150225369A1 (en) *	2012-08-29	2015-08-13	Merck Patent Gmbh	Ddr2 inhibitors for the treatment of osteoarthritis
US9688635B2 (en)	2012-09-24	2017-06-27	Neupharma, Inc.	Certain chemical entities, compositions, and methods
CN103102315B (zh) *	2012-11-01	2016-01-20	云南大学	一种喹唑啉类芳基脲及其制备方法和用途
WO2014075077A1 (en)	2012-11-12	2014-05-15	Neupharma, Inc.	Certain chemical entities, compositions, and methods
US9732063B2 (en)	2012-11-16	2017-08-15	Respivert Limited	Kinase inhibitors
WO2014127335A1 (en) *	2013-02-15	2014-08-21	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
EP2956138B1 (en)	2013-02-15	2022-06-22	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
EA025561B1 (ru)	2013-03-11	2017-01-30	Игнита, Инк.	Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
WO2014140582A1 (en)	2013-03-14	2014-09-18	Respivert Limited	Kinase inhibitors
EP2981534B1 (en)	2013-04-02	2017-07-19	Topivert Pharma Limited	Kinase inhibitors based upon n-alkyl pyrazoles
CN103159685A (zh) *	2013-04-11	2013-06-19	苏州立新制药有限公司	4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
AU2014353006B2 (en) *	2013-11-20	2019-04-04	Signalchem Life Sciences Corp.	Quinazoline derivatives as TAM family kinase inhibitors
PT3357919T (pt)	2014-02-14	2020-02-20	Respivert Ltd	Compostos heterocíclicos aromáticos como compostos antiinflamatórios
SG11201608303QA (en)	2014-04-04	2016-11-29	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015171833A1 (en) *	2014-05-06	2015-11-12	The Regents Of The University Of California	Wound healing using braf inhibitors
CN104892530A (zh) *	2015-05-27	2015-09-09	烟台大学	一种含喹唑啉结构的二芳基脲类化合物及其制备方法和应用
CN104892529A (zh) *	2015-05-27	2015-09-09	烟台大学	一种含喹唑啉结构的硫脲类化合物及其制备方法和应用
BR112018000808A2 (pt) *	2015-07-16	2018-09-04	Array Biopharma Inc	compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
JP6740354B2 (ja)	2015-10-05	2020-08-12	ザトラスティーズオブコロンビアユニバーシティーインザシティーオブニューヨーク	オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
EP3548007A4 (en)	2016-12-01	2020-08-12	Ignyta, Inc.	METHOD OF TREATMENT OF CANCER
WO2018136661A1 (en)	2017-01-18	2018-07-26	Andrews Steven W	SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN108530455B (zh) *	2017-03-01	2021-01-12	北京赛特明强医药科技有限公司	脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
WO2019154132A1 (zh)	2018-02-11	2019-08-15	北京赛特明强医药科技有限公司	脲取代的芳环连二噁烷并喹啉类化合物及其制备方法与应用
CN106928069B (zh) *	2017-03-21	2019-03-19	上海玉函化工有限公司	一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法
WO2019005241A1 (en)	2017-03-23	2019-01-03	Clavius Pharmaceuticals, Llc	TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND METHODS OF TREATMENT
CN107501283B (zh)	2017-09-13	2020-06-02	北京师范大学	取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用
CN109721552B (zh) *	2017-10-30	2022-09-20	上海北卡医药技术有限公司	一种吉非替尼的制备方法
CN109721551B (zh) *	2017-10-30	2022-09-20	上海北卡医药技术有限公司	一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
JP7060694B2 (ja)	2018-01-18	2022-04-26	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en)	2018-01-18	2022-10-18	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740490A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN108358798A (zh) *	2018-02-12	2018-08-03	黑龙江鑫创生物科技开发有限公司	一种微通道反应器合成厄洛替尼中间体的方法
WO2019241787A1 (en) *	2018-06-15	2019-12-19	The Regents Of The University Of Colorado A Body Corporate	Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
WO2020041562A1 (en)	2018-08-22	2020-02-27	Clavius Pharmaceuticals, Llc	Substituted imidazoles for the inhibition of tgf-beta and methods of treatment
CN110862398B (zh) *	2018-08-27	2021-04-06	北京赛特明强医药科技有限公司	脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CN112996794A (zh)	2018-09-10	2021-06-18	阿雷生物药品公司	作为ret激酶抑制剂的稠合杂环化合物
JP2022500385A (ja)	2018-09-10	2022-01-04	ミラティセラピューティクス，インコーポレイテッド	組み合わせ療法
CN109553581B (zh) *	2018-09-25	2022-01-25	广州六顺生物科技股份有限公司	取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
TWI849043B (zh) *	2019-01-25	2024-07-21	英屬開曼群島商百濟神州有限公司	B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
KR102534457B1 (ko) *	2019-02-12	2023-05-18	루트리스 파마 엘티디.	방사선 피부염의 치료를 위한 국소 BRaF 억제제 조성물의 용도
AU2020403082A1 (en) *	2019-12-10	2022-05-12	F. Hoffmann-La Roche Ag	New BRAF inhibitors as paradox breakers
PH12022551119A1 (en)	2019-12-10	2023-08-23	Hoffmann La Roche	New methylquinazolinone derivatives
RS65962B1 (sr)	2020-05-08	2024-10-31	Halia Therapeutics Inc	Inhibitori nek7 kinaze
KR102186761B1 (ko)	2020-06-03	2020-12-04	옙바이오 주식회사	2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
US20240400551A1 (en)	2021-01-25	2024-12-05	Halia Therapeutics, Inc.	Nek7 inhibitors
CN113254860B (zh) *	2021-06-04	2022-03-22	南京航空航天大学	一种堆芯栅元中子通量的计算方法
JP2025507542A (ja) *	2022-02-23	2025-03-21	バイオヘイブン・セラピューティクス・リミテッド	Ｋｖ７チャネル活性化剤としてのピラゾリル化合物

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en)	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4410545A (en)	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4409239A (en)	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
DE3209472C2 (de)	1982-03-16	1984-05-17	Degussa Ag, 6000 Frankfurt	Verfahren zur Herstellung von 3-Oxonitrilen sowie neue 3-Oxonitrile
HU196714B (en)	1984-10-04	1989-01-30	Monsanto Co	Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
JPS6296479A (ja)	1985-10-23	1987-05-02	Shionogi & Co Ltd	ポリフルオロアルキルイソオキサゾリルアミン類
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en)	1988-08-30	1997-03-18	Pfizer Inc.	Use of asymmetric membranes in delivery devices
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5585112A (en)	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it)	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en)	1993-03-18	2001-08-14	Cytimmune Sciences, Inc.	Composition and method for delivery of biologically-active factors
US5523092A (en)	1993-04-14	1996-06-04	Emory University	Device for local drug delivery and methods for using the same
US5985307A (en)	1993-04-14	1999-11-16	Emory University	Device and method for non-occlusive localized drug delivery
US6087324A (en)	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
US6004534A (en)	1993-07-23	1999-12-21	Massachusetts Institute Of Technology	Targeted polymerized liposomes for improved drug delivery
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en)	1994-08-05	1998-06-02	New England Deaconess Hospital Corporation	Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en)	1994-11-28	1997-08-26	Haynes; Duncan H	Drug releasing surgical implant or dressing material
US6316652B1 (en)	1995-06-06	2001-11-13	Kosta Steliou	Drug mitochondrial targeting agents
US5798119A (en)	1995-06-13	1998-08-25	S. C. Johnson & Son, Inc.	Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en)	1995-06-27	1997-01-30	Takeda Chemical Industries Ltd.	Method of producing sustained-release preparation
TW448055B (en)	1995-09-04	2001-08-01	Takeda Chemical Industries Ltd	Method of production of sustained-release preparation
JP2909418B2 (ja)	1995-09-18	1999-06-23	株式会社資生堂	薬物の遅延放出型マイクロスフイア
US6039975A (en)	1995-10-17	2000-03-21	Hoffman-La Roche Inc.	Colon targeted delivery system
EP0860433B1 (en) *	1995-11-07	2002-07-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5980945A (en)	1996-01-16	1999-11-09	Societe De Conseils De Recherches Et D'applications Scientifique S.A.	Sustained release drug formulations
TW345603B (en)	1996-05-29	1998-11-21	Gmundner Fertigteile Gmbh	A noise control device for tracks
US6264970B1 (en)	1996-06-26	2001-07-24	Takeda Chemical Industries, Ltd.	Sustained-release preparation
US6419961B1 (en)	1996-08-29	2002-07-16	Takeda Chemical Industries, Ltd.	Sustained release microcapsules of a bioactive substance and a biodegradable polymer
JP2000508339A (ja)	1996-10-01	2000-07-04	シーマ・ラブス・インコーポレイテッド	味隠蔽マイクロカプセル組成物及び製造方法
CA2217134A1 (en)	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
PT839525E (pt)	1996-10-31	2004-10-29	Takeda Chemical Industries Ltd	Preparacao de libertacao prolongada
US6131570A (en)	1998-06-30	2000-10-17	Aradigm Corporation	Temperature controlling device for aerosol drug delivery
WO1998027980A2 (en)	1996-12-20	1998-07-02	Takeda Chemical Industries, Ltd.	Method of producing a sustained-release preparation
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
US6060082A (en)	1997-04-18	2000-05-09	Massachusetts Institute Of Technology	Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US20070244120A1 (en) *	2000-08-18	2007-10-18	Jacques Dumas	Inhibition of raf kinase using substituted heterocyclic ureas
US6350458B1 (en)	1998-02-10	2002-02-26	Generex Pharmaceuticals Incorporated	Mixed micellar drug deliver system and method of preparation
US6613358B2 (en)	1998-03-18	2003-09-02	Theodore W. Randolph	Sustained-release composition including amorphous polymer
US6048736A (en)	1998-04-29	2000-04-11	Kosak; Kenneth M.	Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko)	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US7262201B1 (en)	1998-10-08	2007-08-28	Astrazeneca Ab	Quinazoline derivatives
ATE356117T1 (de) *	1999-01-22	2007-03-15	Kirin Brewery	Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en)	1999-04-14	2001-08-07	Musc Foundation For Research Development	Tissue-specific and pathogen-specific toxic agents and ribozymes
AU2223201A (en)	1999-12-24	2001-07-09	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
BR0113626A (pt)	2000-08-30	2003-06-17	Pfizer Prod Inc	Formulações de liberação sustentada para secretores de hormÈnio do crescimento
AU9598601A (en)	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
DK1382604T3 (da)	2001-04-27	2006-04-18	Kirin Brewery	Quinolinderivater med en azolylgruppe og quinazolinderivater
AU2002313249B2 (en)	2001-06-22	2008-08-21	Kirin Pharma Kabushiki Kaisha	Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
EP2210607B1 (en)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7691866B2 (en)	2003-10-16	2010-04-06	Novartis Vaccines And Diagnostics, Inc.	2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
EP1684762A4 (en)	2003-11-13	2009-06-17	Ambit Biosciences Corp	UREA DERIVATIVES AS MODULATORS OF KINASE
CA2592118C (en)	2004-12-23	2015-11-17	Deciphera Pharmaceuticals, Llc	Urea derivatives as enzyme modulators
US7576090B2 (en)	2004-12-27	2009-08-18	4Sc Ag	Benzazole analogues and uses thereof
EP1746096A1 (en)	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
WO2007071963A2 (en)	2005-12-22	2007-06-28	Astrazeneca Ab	Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
US20070265258A1 (en)	2006-03-06	2007-11-15	Ruiping Liu	Quinazoline derivatives as phosphodiesterase 10 inhibitors
CN101415689A (zh)	2006-04-05	2009-04-22	阿斯利康(瑞典)有限公司	具有抗癌活性的经取代的喹唑啉
JP2009532450A (ja)	2006-04-05	2009-09-10	アストラゼネカアクチボラグ	化合物
MX2009000044A (es)	2006-06-30	2009-01-23	Ambit Bios Corp	Etiqueta de acido nucleico detectable.
CA2666624C (en)	2006-10-19	2015-12-29	Signal Pharmaceuticals, Llc	Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es)	2006-10-19	2016-03-28	Signal Pharm Llc	Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP3147281A1 (en)	2008-03-17	2017-03-29	Ambit Biosciences Corporation	Quinazoline derivatives as raf kinase modulators and methods of use thereof

2009
- 2009-03-17 EP EP16191210.0A patent/EP3147281A1/en not_active Withdrawn
- 2009-03-17 HU HUE09722418A patent/HUE025197T2/en unknown
- 2009-03-17 SG SG2013046388A patent/SG191678A1/en unknown
- 2009-03-17 SI SI200931239T patent/SI2268623T1/sl unknown
- 2009-03-17 SG SG10201608813PA patent/SG10201608813PA/en unknown
- 2009-03-17 PT PT151661410T patent/PT2947072T/pt unknown
- 2009-03-17 HU HUE15166141A patent/HUE032873T2/en unknown
- 2009-03-17 BR BRPI0906186A patent/BRPI0906186A2/pt not_active Application Discontinuation
- 2009-03-17 EA EA201071089A patent/EA019350B1/ru not_active IP Right Cessation
- 2009-03-17 MY MYPI2010004046A patent/MY161576A/en unknown
- 2009-03-17 PL PL09722418T patent/PL2268623T3/pl unknown
- 2009-03-17 CA CA2718123A patent/CA2718123C/en not_active Expired - Fee Related
- 2009-03-17 ES ES09722418.2T patent/ES2547406T3/es active Active
- 2009-03-17 CN CN201610341553.2A patent/CN106146484A/zh active Pending
- 2009-03-17 NZ NZ587907A patent/NZ587907A/xx unknown
- 2009-03-17 EP EP15166141.0A patent/EP2947072B1/en not_active Not-in-force
- 2009-03-17 JP JP2011500793A patent/JP5542793B2/ja not_active Expired - Fee Related
- 2009-03-17 AU AU2009226136A patent/AU2009226136B2/en not_active Ceased
- 2009-03-17 DK DK09722418.2T patent/DK2268623T3/en active
- 2009-03-17 SI SI200931598A patent/SI2947072T1/sl unknown
- 2009-03-17 WO PCT/US2009/001659 patent/WO2009117080A1/en not_active Ceased
- 2009-03-17 US US12/933,402 patent/US8618289B2/en not_active Expired - Fee Related
- 2009-03-17 KR KR1020167000978A patent/KR101713501B1/ko not_active Expired - Fee Related
- 2009-03-17 CA CA2972138A patent/CA2972138A1/en not_active Abandoned
- 2009-03-17 KR KR1020107023083A patent/KR101601997B1/ko not_active Expired - Fee Related
- 2009-03-17 PT PT97224182T patent/PT2268623E/pt unknown
- 2009-03-17 PL PL15166141T patent/PL2947072T3/pl unknown
- 2009-03-17 ES ES15166141.0T patent/ES2610989T3/es active Active
- 2009-03-17 EP EP09722418.2A patent/EP2268623B9/en not_active Not-in-force
- 2009-03-17 CN CN200980116870.2A patent/CN102026985B/zh not_active Expired - Fee Related
- 2009-03-17 DK DK15166141.0T patent/DK2947072T3/en active
- 2009-03-17 MX MX2010010172A patent/MX2010010172A/es active IP Right Grant
2010
- 2010-08-24 IL IL207793A patent/IL207793A/en not_active IP Right Cessation
- 2010-09-10 ZA ZA2010/06524A patent/ZA201006524B/en unknown
2013
- 2013-10-08 US US14/048,655 patent/US8969587B2/en not_active Expired - Fee Related
2015
- 2015-01-26 US US14/605,834 patent/US9320739B2/en not_active Expired - Fee Related
2016
- 2016-03-18 US US15/074,671 patent/US9730937B2/en not_active Expired - Fee Related
2017
- 2017-06-28 US US15/636,562 patent/US10053430B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR101601997B1 (ko)	2016-03-17
SI2947072T1 (sl)	2017-03-31
CA2718123A1 (en)	2009-09-24
EP2268623A1 (en)	2011-01-05
US20110118245A1 (en)	2011-05-19
US20140045868A1 (en)	2014-02-13
US20170298029A1 (en)	2017-10-19
KR20160012243A (ko)	2016-02-02
DK2268623T3 (en)	2015-06-29
PL2268623T3 (pl)	2015-10-30
SI2268623T1 (sl)	2016-01-29
EA019350B1 (ru)	2014-03-31
ES2547406T3 (es)	2015-10-06
ES2610989T3 (es)	2017-05-04
PL2947072T3 (pl)	2017-05-31
DK2947072T3 (en)	2017-01-23
HUE025197T2 (en)	2016-02-29
EP2268623B9 (en)	2018-02-28
US20150246042A1 (en)	2015-09-03
KR20110003340A (ko)	2011-01-11
EP2947072B1 (en)	2016-11-09
MX2010010172A (es)	2010-11-25
EP2947072A1 (en)	2015-11-25
AU2009226136B2 (en)	2013-08-15
KR101713501B1 (ko)	2017-03-07
WO2009117080A1 (en)	2009-09-24
JP2011529021A (ja)	2011-12-01
CN102026985A (zh)	2011-04-20
WO2009117080A8 (en)	2010-11-04
IL207793A (en)	2014-11-30
PT2268623E (pt)	2015-09-17
AU2009226136A1 (en)	2009-09-24
EP2268623B1 (en)	2015-05-06
EP3147281A1 (en)	2017-03-29
CN102026985B (zh)	2016-07-06
ZA201006524B (en)	2013-02-27
US8618289B2 (en)	2013-12-31
IL207793A0 (en)	2010-12-30
SG10201608813PA (en)	2016-12-29
CN106146484A (zh)	2016-11-23
US9730937B2 (en)	2017-08-15
HK1151525A1 (en)	2012-02-03
US9320739B2 (en)	2016-04-26
US10053430B2 (en)	2018-08-21
US20160199375A1 (en)	2016-07-14
CA2718123C (en)	2017-08-22
HUE032873T2 (en)	2017-11-28
NZ587907A (en)	2012-09-28
EA201071089A1 (ru)	2011-04-29
SG191678A1 (en)	2013-07-31
US8969587B2 (en)	2015-03-03
MY161576A (en)	2017-04-28
CA2972138A1 (en)	2009-09-24
BRPI0906186A2 (pt)	2015-09-22
JP5542793B2 (ja)	2014-07-09
HK1216100A1 (en)	2016-10-14

Publication	Publication Date	Title
PT2947072T (pt)	2016-12-06	1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
WO2011053938A8 (en)	2011-08-11	Methods and compositions for treating cancer
IL199673A0 (en)	2010-04-15	5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
NZ593004A (en)	2013-05-31	Azaazulene compounds
AP2010005508A0 (en)	2010-12-31	Triazole derivatives useful for the treatment of diseases.
CL2013000884A1 (es)	2013-10-18	El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer.
IL202505A (en)	2014-11-30	2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
NZ607795A (en)	2015-02-27	Estrogen receptor modulators and uses thereof
HUE059861T2 (hu)	2023-01-28	N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
NZ629636A (en)	2017-02-24	Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
LT3252069T (lt)	2019-06-10	(11.beta.,17.beta.)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuormetil)estra-4,9-dien-3-onas, skirtas naudoti ligų gydymui
IL237378B (en)	2019-10-31	Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them
IL206470A (en)	2014-07-31	2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
NZ611314A (en)	2015-06-26	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
IL200403A0 (en)	2010-04-29	Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
SI2632921T1 (sl)	2019-01-31	Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
ZA201003965B (en)	2011-03-30	1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
ZA201002854B (en)	2011-10-26	Amino 1,2,4-triazole derivatives as modulators of mglur5
IL179346A0 (en)	2007-03-08	3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
PL1896425T3 (pl)	2011-04-29	Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
ZA200809565B (en)	2009-09-30	4-(2, e-dichloro-benzoylamino)-1H-pyrazole-s-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer
AU2008339005A8 (en)	2010-07-01	3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
ZA201103134B (en)	2012-01-25	(pyrrolidin-2 yl) phenyl derivatives for use in the treatment of pain
ZA200809554B (en)	2010-01-27	3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides
ZA200710457B (en)	2008-11-26	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide